UY32005A - Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a - Google Patents
Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico aInfo
- Publication number
- UY32005A UY32005A UY0001032005A UY32005A UY32005A UY 32005 A UY32005 A UY 32005A UY 0001032005 A UY0001032005 A UY 0001032005A UY 32005 A UY32005 A UY 32005A UY 32005 A UY32005 A UY 32005A
- Authority
- UY
- Uruguay
- Prior art keywords
- derivatives
- stratriene
- bioisosters
- include heterocyclic
- phenolic ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Nuevos derivados de pirazolo-estrieno y triazolo-estrieno, composiciones farmacéuticas que los contienen y su uso en el tratamiento o la prevención de trastornos y enfermedades mediados por un receptor de estrógeno; y como agentes anticonceptivos, solos o en combinación con un progestógeno o un antagonista de un progestógeno. Los compuestos de la invención son moduladores selectivos del receptor de estrógeno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08161108A EP2147924A1 (en) | 2008-07-24 | 2008-07-24 | Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32005A true UY32005A (es) | 2010-02-26 |
Family
ID=40329347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032005A UY32005A (es) | 2008-07-24 | 2009-07-23 | Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a |
Country Status (24)
Country | Link |
---|---|
US (1) | US20110190246A1 (es) |
EP (2) | EP2147924A1 (es) |
JP (1) | JP2011528675A (es) |
KR (1) | KR20110036739A (es) |
CN (1) | CN102105484A (es) |
AR (1) | AR072533A1 (es) |
AU (1) | AU2009273494A1 (es) |
BR (1) | BRPI0915987A2 (es) |
CA (1) | CA2731634A1 (es) |
CL (1) | CL2011000153A1 (es) |
CO (1) | CO6351799A2 (es) |
CR (1) | CR20110045A (es) |
DO (1) | DOP2011000024A (es) |
EA (1) | EA201100226A1 (es) |
EC (1) | ECSP11010780A (es) |
IL (1) | IL210314A0 (es) |
MA (1) | MA32477B1 (es) |
MX (1) | MX2011000939A (es) |
PE (1) | PE20110402A1 (es) |
SV (1) | SV2011003817A (es) |
TW (1) | TW201008570A (es) |
UY (1) | UY32005A (es) |
WO (1) | WO2010009828A1 (es) |
ZA (1) | ZA201101445B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011092127A1 (en) * | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
JP2023526568A (ja) * | 2020-05-15 | 2023-06-21 | シムサー ファーマシューティカル カンパニー リミテッド | ピロリジン化合物及びその使用 |
DE102022109544A1 (de) | 2022-04-20 | 2023-10-26 | Eberspächer Catem Gmbh & Co. Kg | Elektrische Heizvorrichtung |
DE102022109556A1 (de) | 2022-04-20 | 2023-10-26 | Eberspächer Catem Gmbh & Co. Kg | Elektrische Heizvorrichtung |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3458504A (en) * | 1966-10-24 | 1969-07-29 | Sterling Drug Inc | Steroido(3,4-c)pyrazoles of the 5alpha- and 5beta-androstane series |
CA2491132A1 (en) * | 2002-07-03 | 2004-01-15 | Ortho-Mcneil Pharmaceutical, Inc. | Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
-
2008
- 2008-07-24 EP EP08161108A patent/EP2147924A1/en not_active Withdrawn
-
2009
- 2009-07-14 PE PE2011000072A patent/PE20110402A1/es not_active Application Discontinuation
- 2009-07-14 JP JP2011519066A patent/JP2011528675A/ja active Pending
- 2009-07-14 CN CN2009801289641A patent/CN102105484A/zh active Pending
- 2009-07-14 WO PCT/EP2009/005086 patent/WO2010009828A1/en active Application Filing
- 2009-07-14 US US13/055,388 patent/US20110190246A1/en not_active Abandoned
- 2009-07-14 AU AU2009273494A patent/AU2009273494A1/en not_active Abandoned
- 2009-07-14 BR BRPI0915987A patent/BRPI0915987A2/pt not_active IP Right Cessation
- 2009-07-14 KR KR1020117001617A patent/KR20110036739A/ko not_active Application Discontinuation
- 2009-07-14 EA EA201100226A patent/EA201100226A1/ru unknown
- 2009-07-14 CA CA2731634A patent/CA2731634A1/en not_active Abandoned
- 2009-07-14 MX MX2011000939A patent/MX2011000939A/es not_active Application Discontinuation
- 2009-07-14 EP EP09800008A patent/EP2307439A1/en not_active Withdrawn
- 2009-07-20 TW TW098124460A patent/TW201008570A/zh unknown
- 2009-07-23 UY UY0001032005A patent/UY32005A/es not_active Application Discontinuation
- 2009-07-24 AR ARP090102822A patent/AR072533A1/es unknown
-
2010
- 2010-12-28 IL IL210314A patent/IL210314A0/en unknown
-
2011
- 2011-01-14 MA MA33521A patent/MA32477B1/fr unknown
- 2011-01-20 DO DO2011000024A patent/DOP2011000024A/es unknown
- 2011-01-24 CR CR20110045A patent/CR20110045A/es not_active Application Discontinuation
- 2011-01-24 CL CL2011000153A patent/CL2011000153A1/es unknown
- 2011-01-24 SV SV2011003817A patent/SV2011003817A/es unknown
- 2011-01-24 EC EC2011010780A patent/ECSP11010780A/es unknown
- 2011-01-25 CO CO11007864A patent/CO6351799A2/es not_active Application Discontinuation
- 2011-02-23 ZA ZA2011/01445A patent/ZA201101445B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20110402A1 (es) | 2011-06-19 |
US20110190246A1 (en) | 2011-08-04 |
JP2011528675A (ja) | 2011-11-24 |
TW201008570A (en) | 2010-03-01 |
DOP2011000024A (es) | 2011-02-28 |
KR20110036739A (ko) | 2011-04-08 |
BRPI0915987A2 (pt) | 2019-09-24 |
EP2147924A1 (en) | 2010-01-27 |
CA2731634A1 (en) | 2010-01-28 |
SV2011003817A (es) | 2011-05-20 |
MA32477B1 (fr) | 2011-07-03 |
CO6351799A2 (es) | 2011-12-20 |
ECSP11010780A (es) | 2011-02-28 |
AU2009273494A1 (en) | 2010-01-28 |
CN102105484A (zh) | 2011-06-22 |
ZA201101445B (en) | 2012-07-25 |
WO2010009828A1 (en) | 2010-01-28 |
MX2011000939A (es) | 2011-03-04 |
CL2011000153A1 (es) | 2011-07-08 |
AR072533A1 (es) | 2010-09-01 |
EP2307439A1 (en) | 2011-04-13 |
EA201100226A1 (ru) | 2011-08-30 |
IL210314A0 (en) | 2011-03-31 |
CR20110045A (es) | 2012-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001809A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15). | |
PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
PH12015501737B1 (en) | Androgen receptor modulators and uses thereof | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
CL2008002521A1 (es) | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. | |
UY32225A (es) | Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2 | |
MX2015016171A (es) | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
CO6410295A2 (es) | Derivados de indol como antagonistas del receptor crth2 | |
DOP2010000234A (es) | Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina | |
CL2007000396A1 (es) | Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos. | |
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
CL2011000570A1 (es) | Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras. | |
UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181108 |